Tango Therapeutics (TNGX) R&D president sells 54,345 company shares

Rhea-AI Filing Summary

Tango Therapeutics, Inc. reported that Crystal Adam, its President, R&D, sold 54,345 shares of common stock on February 25, 2026. The open-market sale was executed at a weighted average price of $12.7741 per share under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025. Following this transaction, Adam directly owns 132,873 Tango Therapeutics common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crystal Adam

(Last) (First) (Middle)

C/O TANGO THERAPEUTICS, INC.,

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON MA 02215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		S(1)		54,345	D	$12.7741(2)	132,873	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.

2. Represents the weighted average sales price per share. The shares sold at prices ranging from $12.61 to $13.09 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Julie Fogarty, as attorney-in-fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tango Therapeutics (TNGX) disclose for Crystal Adam?

Tango Therapeutics disclosed that Crystal Adam, President of R&D, sold 54,345 shares of common stock. The sale occurred on February 25, 2026, as an open-market transaction at a weighted average price of $12.7741 per share under a Rule 10b5-1 trading plan.

How many Tango Therapeutics (TNGX) shares did Crystal Adam sell and at what price?

Crystal Adam sold 54,345 shares of Tango Therapeutics common stock at a weighted average price of $12.7741 per share. The shares were sold in open-market transactions within a range from $12.61 to $13.09 per share, according to the Form 4 footnote disclosure.

Does Crystal Adam still hold Tango Therapeutics (TNGX) shares after the reported sale?

Yes. After selling 54,345 shares, Crystal Adam directly owns 132,873 shares of Tango Therapeutics common stock. This post-transaction holding reflects her remaining direct ownership position as reported in the Form 4 insider trading disclosure filed with regulators.

Was the Tango Therapeutics (TNGX) insider sale under a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were effected under a Rule 10b5-1 trading plan adopted on October 27, 2025. Such plans allow insiders to pre-schedule trades, helping separate personal trading decisions from subsequent non-public company developments.

What role does Crystal Adam hold at Tango Therapeutics (TNGX)?

Crystal Adam serves as President, R&D at Tango Therapeutics, Inc. Her Form 4 filing reflects an open-market sale of 54,345 company shares, providing transparency into equity transactions by a key research and development executive at the biotechnology company.

What price range applied to Crystal Adam’s Tango Therapeutics (TNGX) share sales?

The filing notes a weighted average sale price of $12.7741 per share, with individual trades executed between $12.61 and $13.09 per share. Detailed share counts at each specific price level are available upon request from the company, regulators, or shareholders.